{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:12:48Z","timestamp":1784632368869,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T00:00:00Z","timestamp":1427328000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.ijrobp.2015.02.012","type":"journal-article","created":{"date-parts":[[2015,3,14]],"date-time":"2015-03-14T05:48:38Z","timestamp":1426312118000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma: A Population-Based Analysis"],"prefix":"10.1016","volume":"92","clinical-trial-number":[{"clinical-trial-number":"nct00302003","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Naamit K.","family":"Gerber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral L.","family":"Atoria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena B.","family":"Elkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-8585","authenticated-orcid":false,"given":"Joachim","family":"Yahalom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.02.012_bib1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","article-title":"Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: Report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease","volume":"17","author":"Diehl","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib2","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.2007.11.8869","article-title":"Lymphocyte-predominant and classical Hodgkin's lymphoma: A comprehensive analysis from the German Hodgkin Study Group","volume":"26","author":"Nogova","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib3","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2013-07-453241","article-title":"How I treat nodular lymphocyte predominant Hodgkin lymphoma","volume":"122","author":"Advani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib4","first-page":"367","article-title":"Nodular lymphocyte predominant Hodgkin's lymphoma","volume":"142","author":"Fanale","year":"2008","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib5","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/cncr.21995","article-title":"Hodgkin disease survival in Europe and the U.S.: Prognostic significance of morphologic groups","volume":"107","author":"Allemani","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib6","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"Feugier","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib7","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1182\/blood-2013-12-541078","article-title":"Advanced stage nodular lymphocyte predominant Hodgkin's lymphoma compared to classical Hodgkin lymphoma: A matched pair outcome analysis","volume":"123","author":"Xing","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib8","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.3109\/10428194.2010.525724","article-title":"Comparing adult and pediatric Hodgkin lymphoma in the Surveillance, Epidemiology and End Results Program, 1988-2005: An analysis of 21,734 cases","volume":"51","author":"Bazzeh","year":"2010","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib9","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.ijrobp.2010.10.069","article-title":"The declining utilization of radiation therapy in stage I and II Hodgkin's disease and its impact on survival and secondary malignancies","volume":"82","author":"Koshy","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib10","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3109\/10428194.2013.847938","article-title":"Disparate survival and risk of secondary non-Hodgkin lymphoma in histologic subtypes of Hodgkin lymphoma: A population-based study","volume":"55","author":"Ali","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib11","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1200\/JCO.1997.15.9.3060","article-title":"Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease","volume":"15","author":"Bodis","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib12","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1200\/JCO.2005.04.5823","article-title":"Hodgkin's lymphoma in adolescents","volume":"24","author":"Foltz","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/annonc\/mdr378","article-title":"Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"22","author":"Eichenauer","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1200\/JCO.2009.24.0945","article-title":"Early-stage, lymphocyte-predominant Hodgkin's lymphoma: Patient outcomes from a large, single-institution series with long follow-up","volume":"28","author":"Chen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib15","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","article-title":"Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: A retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group","volume":"104","author":"Wirth","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib16","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","article-title":"Radiotherapy alone for lymphocyte-predominant Hodgkin's disease","volume":"8","author":"Schlembach","year":"2002","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib17","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/annonc\/mdq063","article-title":"Lymphocyte-predominant Hodgkin lymphoma\u2014Clinical features and treatment outcomes from a 30-year experience","volume":"21","author":"Jackson","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib18","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1182\/blood-2011-07-365932","article-title":"Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome","volume":"118","author":"Savage","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib19","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1182\/blood.V124.21.3054.3054","article-title":"Management and outcomes of nodular lymphocyte predominant hodgkin lymphoma: A retrospective study by the lymphoma study association","volume":"124","author":"Lazarovici","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib20","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1182\/blood.V124.21.3058.3058","article-title":"Treatment of stage IA nodular lymphocyte-predominant hodgkin lymphoma (NLPHL): An analysis from the German Hodgkin Study Group (GHSG)","volume":"124","author":"Eichenauer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib21","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00043426-200309000-00003","article-title":"Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents","volume":"25","author":"Murphy","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib22","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","article-title":"Lymphocyte-predominant Hodgkin's lymphoma in children: Therapeutic abstention after initial lymph node resection\u2014A study of the French Society of Pediatric Oncology","volume":"21","author":"Pellegrino","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/cncr.22762","article-title":"Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma","volume":"110","author":"Mauz-Korholz","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib24","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.2013.53.2069","article-title":"Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma","volume":"32","author":"Advani","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib25","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","article-title":"Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial","volume":"101","author":"Ekstrand","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib26","doi-asserted-by":"crossref","first-page":"4363","DOI":"10.1182\/blood-2011-06-361055","article-title":"Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group","volume":"118","author":"Eichenauer","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib27","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.02.012_bib28","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a059244","article-title":"Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases","volume":"6","author":"Pappa","year":"1995","journal-title":"Ann Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615001790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615001790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T21:42:26Z","timestamp":1598823746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615001790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0360301615001790"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.02.012","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristics and Outcomes of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Versus Those With Classical Hodgkin Lymphoma: A Population-Based Analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.02.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}